46 filings · most recent first
AXSM 8-K Filings
Axsome Therapeutics Nda For Axs12 Accepted By Fda For Cataplexy In Narcolepsy
Axsome Therapeutics Receives Paragraph Iv Certification Notice Letter From
Axsome Therapeutics Adopts New Executive Severance Plan
Axsome Therapeutics Announces Election Results From 2026 Annual Meeting
Axsome Therapeutics Settles All Sunosi Patent Litigation
Axsome Therapeutics Reports Strong Q1 2026 Financial Results And Business Update
Axsome Therapeutics Receives Fda Approval For Auvelity To Treat Agitation In
Axsome Therapeutics Acquires Balipodect For Neuropsychiatric Treatments
Axsome Therapeutics Reports Strong Q4 And Full Year 2025 Financial Results
Axsome Therapeutics Settles Sunosi Patent Litigation With Alkem Laboratories
Axsome Therapeutics Reports Preliminary 2025 Revenue Growth Of 6566
Axsome Therapeutics Receives Fda Priority Review For Alzheimers Disease
Axsome Therapeutics Reports Strong Third Quarter 2025 Financial Results And
Axsome Therapeutics Reports Strong Q2 2025 Financial Results And Business
Axsome Therapeutics Launches Symbravo For Migraine Treatment
Axsome Therapeutics Annual Meeting Proposals Passed
Fda Issues Refusal To File For Axsomes Nda For Axs14 For Fibromyalgia
Axsome Therapeutics Settles Sunosi Patent Litigation With Hetero Labs Ltd
Axsome Therapeutics Enters 570M Loan And Credit Facility With Blackstone
Axsome Therapeutics Reports Strong First Quarter 2025 Financial Results And
Axsome Therapeutics Announces Topline Results From Paradigm Phase 3 Trial For
Axsome Therapeutics Announces Successful Phase 3 Trial Results For Solriamfetol
Axsome Therapeutics Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Axsome Therapeutics Announces Fda Prenda Meeting Minutes For Axs05 In
Axsome Therapeutics Reports Strong Financial Results And Pipeline Progress For
Axsome Therapeutics Settles Auvelity Patent Litigation With Teva Pharmaceuticals
Axsome Therapeutics Receives Fda Approval For Symbravo Migraine Treatment
Axsome Therapeutics Reports Preliminary Fourth Quarter And Full Year 2024 Net
Axsome Therapeutics Announces Successful Phase 3 Clinical Trial Results For
Axsome Therapeutics Announces Positive Results For Axs12 In Narcolepsy Phase 3
Axsome Therapeutics Announces Strong Q3 2024 Financial Results And Business
Axsome Therapeutics Amends Loan Agreement
Axsome Therapeutics Resubmits Nda For Migraine Treatment Axs07
Axsome Therapeutics Dismisses Patent Litigation For Sunosi With Sandoz Inc
Axsome Therapeutics Reports Strong Q2 2024 Financial Results And Pipeline
Axsome Therapeutics 2024 Annual Meeting Proposals Passed
Axsome Therapeutics Settles Sunosi Patent Litigation With Unichem Laboratories
Axsome Therapeutics Reports Strong Q1 2024 Financial Results And Pipeline
Axsome Therapeutics Initiates Phase 3 Trial For Solriamfetol In Binge Eating
Axsome Therapeutics Reports High Unmet Needs In Treated Narcolepsy Type 1
Axsome Therapeutics Announces Successful Phase 3 Trial Results For Axs12 In
Axsome Therapeutics Initiates Phase 3 Trial For Solriamfetol In Major
Axsome Therapeutics Updates Corporate Presentation
Axsome Therapeutics Reports Strong 2023 Financial Performance And Provides
Axsome Therapeutics Updates Corporate Presentation
Axsome Therapeutics Reports Preliminary 2023 Revenue And 2024 Milestones